ZYUS Life Sciences (TSXV:ZYUS) FCF Margin % : -3,101.03% (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is ZYUS Life Sciences FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. ZYUS Life Sciences's Free Cash Flow for the three months ended in Dec. 2023 was C$-3.01 Mil. ZYUS Life Sciences's Revenue for the three months ended in Dec. 2023 was C$0.10 Mil. Therefore, ZYUS Life Sciences's FCF Margin % for the quarter that ended in Dec. 2023 was -3,101.03%.

As of today, ZYUS Life Sciences's current FCF Yield % is -24.59%.

The historical rank and industry rank for ZYUS Life Sciences's FCF Margin % or its related term are showing as below:

TSXV:ZYUS' s FCF Margin % Range Over the Past 10 Years
Min: -10555.07 Med: -5211.68 Max: -3400.67
Current: -5211.68

During the past 3 years, the highest FCF Margin % of ZYUS Life Sciences was -3400.67%. The lowest was -10555.07%. And the median was -5211.68%.

TSXV:ZYUS's FCF Margin % is ranked worse than
98.44% of 1028 companies
in the Drug Manufacturers industry
Industry Median: -0.05 vs TSXV:ZYUS: -5211.68

ZYUS Life Sciences FCF Margin % Historical Data

The historical data trend for ZYUS Life Sciences's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ZYUS Life Sciences FCF Margin % Chart

ZYUS Life Sciences Annual Data

Trend

Dec21

Dec22

Dec23

FCF Margin %

-10,555.07

-3,400.67

-5,211.68

ZYUS Life Sciences Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial				-2,789.33	-2,152.56	1,801.30	-15,144.44	-3,101.03

Competitive Comparison of ZYUS Life Sciences's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, ZYUS Life Sciences's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ZYUS Life Sciences's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ZYUS Life Sciences's FCF Margin % distribution charts can be found below:

* The bar in red indicates where ZYUS Life Sciences's FCF Margin % falls into.

ZYUS Life Sciences FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

ZYUS Life Sciences's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-18.293	/	0.351
	=	-5,211.68 %

ZYUS Life Sciences's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-3.008	/	0.097
	=	-3,101.03 %

ZYUS Life Sciences FCF Margin % Related Terms

Thank you for viewing the detailed overview of ZYUS Life Sciences's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

ZYUS Life Sciences (TSXV:ZYUS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ZYUS Life Sciences Corp (TSXV:ZYUS) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

ZLSCF:USA

Address

407 Downey Road, Unit 204, Saskatoon, SK, CAN, S7N 4L8

Website

https://www.zyus.com

ZYUS Life Sciences Corp is a next-generation life sciences company engaged in scientific research and development in phyto-therapeutics, including cannabinoid and protein-based formulations. It is committed to delivering high-quality standardized therapeutic formulations that comply with Good Manufacturing Practices (GMP) to provide targeted relief for patients in Canada and globally.

Executives

John Michael Hyshka

Senior Officer

ZYUS Life Sciences (TSXV:ZYUS) Headlines

No Headlines